EFFICACY OF DESENSITIZATION THERAPY FOR ALLERGY TO FACTOR IX CONCENTRATES

DOI Web Site 15 References Open Access
  • Suzuki Nobuaki
    Department of Transfusion Medicine, Nagoya University Hospital
  • Kanematsu Takeshi
    Department of Clinical Laboratory, Nagoya University Hospital
  • Kishimoto Mayuko
    Department of Clinical Laboratory, Nagoya University Hospital
  • Suzuki Naruko
    Department of Hematology and Oncology, Nagoya University Graduate School of Medicine
  • Okamoto Shuichi
    Department of Clinical Laboratory, Nagoya University Hospital
  • Tamura Shogo
    Division of Cellular and Genetic Sciences, Department of Integrated Health Sciences, Nagoya University Graduate School of Medicine
  • Kiyoi Hitoshi
    Department of Hematology and Oncology, Nagoya University Graduate School of Medicine
  • Matsushita Tadashi
    Department of Transfusion Medicine, Nagoya University Hospital Department of Clinical Laboratory, Nagoya University Hospital

Bibliographic Information

Other Title
  • 血液凝固第IX因子濃縮製剤へのアレルギーに対する減感作療法の有効性

Search this article

Description

<p>We report two cases of hemophilia B with severe allergy to factor IX concentrates who responded well to desensitization therapy (DT). Case 1 is a 9-month-old boy with severe hemophilia B who developed anaphylaxis on the 10th exposure day (ED) to recombinant factor IX (rFIX) after starting primary prophylaxis. Case 2 is a 55-year-old male with moderate hemophilia B. He received on-demand plasma-derived FIX (pdFIX) for bleeding symptoms and developed anaphylaxis after the 4th ED to pdFIX. DT with rFIX was performed for case 1 and 2. Results: FIX allergy symptoms disappeared in both cases after DT. No adverse events were observed during DT, including allergic symptoms. Discussion: Case 2 developed anaphylaxis despite his disease severity being moderate and risk of allergy considered low. Both patients were suspected of having low inhibitor levels before and after the onset of anaphylaxis, suggesting that attention to the onset of inhibitors may be predictive of anaphylaxis. The treatment protocol for DT remains to be optimized and requires further investigation.</p>

Journal

References(15)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top